# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|-------|-------|
| QA Report ID | QA-PP-0125 |
| Population Package | PP-0125 |
| Version | 1.0.0 |
| Review Status | PASS |

---

# Layer 1 — Content QA

| Criterion | Result |
|-----------|--------|
| Single educational question | PASS |
| Scope respected | PASS |
| Complete coverage | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Knowledge blocks complete | PASS |
| No overlap with adjacent Population Packages | PASS |

---

# Layer 2 — Clinical QA

| Criterion | Result |
|-----------|--------|
| Scientifically accurate | PASS |
| Consistent with ACMG | PASS |
| Consistent with AMP | PASS |
| Consistent with ClinGen SVI | PASS |
| Consistent with CAP | PASS |
| Consistent with NCI | PASS |
| Consistent with NCCN | PASS |
| Consistent with ASCO | PASS |
| Consistent with ACS | PASS |
| Consistent with ESMO | PASS |
| Appropriate explanation of PM2 | PASS |
| Appropriate explanation of population databases | PASS |
| Appropriate explanation of rare genetic variants | PASS |
| Appropriate distinction between rarity and pathogenicity | PASS |
| Appropriate clarification that PM2 provides moderate—not definitive—evidence | PASS |
| No unsupported clinical claim | PASS |
| No unsafe medical advice | PASS |

---

# Layer 3 — Educational QA

| Criterion | Result |
|-----------|--------|
| Plain language | PASS |
| Appropriate for patients | PASS |
| Learning objectives satisfied | PASS |
| Common misconceptions addressed | PASS |
| Appropriate explanation that population databases provide reference information rather than diagnostic answers | PASS |
| Appropriate clarification that many rare variants are completely benign | PASS |
| Encourages discussion with healthcare professionals | PASS |

---

# Layer 4 — Governance QA

| Criterion | Result |
|-----------|--------|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| Evidence traceability complete | PASS |
| Scope maintained | PASS |
| Knowledge Graph complete | PASS |
| Versioning complete | PASS |
| Repository compliant | PASS |

---

# Clinical Safety Review

| Item | Result |
|------|--------|
| No unsafe medical advice | PASS |
| No unsupported interpretation guidance | PASS |
| Appropriate clarification that PM2 is not equivalent to a pathogenic diagnosis | PASS |
| Appropriate clarification that rarity represents one category of evidence rather than definitive proof | PASS |
| Appropriate explanation that expert interpretation remains essential | PASS |
| No disease-specific treatment recommendations | PASS |

---

# Educational Boundary Review

The Population Package successfully remains within the predefined educational boundary.

Included:

- definition of PM2;
- concept of population databases;
- concept of rare genetic variants;
- purpose of PM2;
- relationship to ACMG variant interpretation;
- patient implications.

Excluded:

- gnomAD;
- population database architecture;
- allele-frequency calculations;
- population genetics;
- founder effects;
- ancestry-specific interpretation;
- ClinGen implementation specifications;
- laboratory workflow;
- treatment recommendations.

The **Atomic Knowledge Principle** has been fully preserved.

---

# Final Quality Decision

## PASS

PP-0125 satisfies the locked **Gold Population Package Specification v1.0**.

Approved as the official Population Package for:

> **PP-0125 — PM2 (Absent or Rare in Population Databases)**

---

# Reviewer Notes

This Population Package introduces **PM2**, one of the core **Moderate Pathogenic Evidence** codes within the ACMG/AMP framework, by explaining how information from **large population reference databases** contributes to professional variant interpretation. It clearly distinguishes **variant rarity** from **pathogenicity**, correcting the common misconception that a rare variant is automatically harmful. Advanced concepts—including allele-frequency thresholds, population genetics, ancestry-specific interpretation, database architecture, and ClinGen implementation guidance—are intentionally deferred to dedicated Population Packages, preserving full compliance with the **Atomic Knowledge Principle**.